Prelude Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Prelude Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$100K	Buy	17,685 +1,613	+10%	+$13K	0.01%	1112
2026 Q1	$147K	Sell	16,072 -154,152	-91%	-$2.17M	0.01%	981
2025 Q4	$2.72M	Buy	+170,224	New	+$4.96M	0.2%	108
2024 Q1	–	Sell	-4,083	Closed	-$74.9K	–	1560
2023 Q4	$74.9K	Sell	4,083 -43	-1%	-$710	0.01%	1050
2023 Q3	$71.6K	Sell	4,126 -1,665	-29%	-$29K	﹤0.01%	1018
2023 Q2	$105K	Buy	5,791 +1,205	+26%	+$24.1K	0.01%	926
2023 Q1	$78.6K	Sell	4,586 -300	-6%	-$4.85K	﹤0.01%	975
2022 Q4	$114K	Buy	4,886 +186	+4%	+$4.31K	0.01%	1060
2022 Q3	$104K	Buy	4,700 +1,206	+35%	+$28.7K	﹤0.01%	1163
2022 Q2	$67K	Buy	+3,494	New	+$77.9K	﹤0.01%	1464

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Prelude Capital Management's LENZ Position: Q2 2026 in Review

Prelude Capital Management increased its LENZ Therapeutics (LENZ) stake by 10% in Q2 2026, buying an estimated $13K and bringing the position to 17,685 shares worth $100K. The position accounts for 0.01% of the portfolio, ranked #1112.

Prelude Capital Management first reported a position in LENZ in Q2 2022 and has held it in 10 quarters since. The position peaked at $2.72M in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

Prelude Capital Management held 17,685 shares of LENZ Therapeutics worth $100K as of Q2 2026.
Prelude Capital Management bought 1,613 LENZ Therapeutics shares in Q2 2026, an estimated $13K.
LENZ Therapeutics made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1112 holding.
Prelude Capital Management first reported a position in LENZ Therapeutics in Q2 2022 and has held it in 10 quarters since.
Prelude Capital Management's LENZ Therapeutics position peaked at $2.72M in Q4 2025.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.